An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DermTech Management to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DermTech, Inc. (NASDAQ: DMTK) announced its participation in key healthcare conferences. Management will meet with investors at the 11th Annual SVB Leerink Global Healthcare Conference on February 16-17, 2022. Additionally, they will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 1:00 p.m. Eastern Time. DermTech is focused on precision dermatology, utilizing a non-invasive skin genomics platform for early skin cancer detection and treatment customization.
Positive
None.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will participate at the following conferences:
11th Annual SVB Leerink Global Healthcare Conference Participating in investor meetings on February 16-17, 2022
BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Presenting on Wednesday, February 16, 2022 at 1:00 p.m. Eastern Time The webcast link is available only for those who are attending the BTIG conference.
About DermTech:
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at: www.dermtech.com.
What conferences is DermTech attending in February 2022?
DermTech will attend the 11th Annual SVB Leerink Global Healthcare Conference on February 16-17, 2022, and present at the BTIG MedTech Conference on February 16, 2022.
What is the focus of DermTech's presentation at the BTIG conference?
At the BTIG MedTech Conference, DermTech will focus on its non-invasive skin genomics platform for early skin cancer detection and treatment customization.
What is DermTech's mission?
DermTech's mission is to transform dermatology through its non-invasive skin genomics platform, democratizing access to high-quality dermatology care.
What innovation does DermTech provide in dermatology?
DermTech utilizes a non-invasive skin sampling method to analyze genomic data for early detection of skin cancers and assessment of inflammatory diseases.
How can I learn more about DermTech?
For more information about DermTech, visit their investor relations site at www.dermtech.com.
